Trials / Terminated
TerminatedNCT05707676
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
A Phase I，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors
Detailed description
This first time in patients, open-label, multi-center study will have LB4330 administered intravenously (IV) in Patients with Advanced Solid Tumors. This study will have 2 parts: Part A which will have dose escalation cohorts and Part B which will have the dose expansion cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LB4330 | LB4330 |
Timeline
- Start date
- 2022-11-30
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
- First posted
- 2023-02-01
- Last updated
- 2025-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05707676. Inclusion in this directory is not an endorsement.